PL3013855T3 - Zmutowany czynnik viii – kompozycje i sposoby wytwarzania - Google Patents

Zmutowany czynnik viii – kompozycje i sposoby wytwarzania

Info

Publication number
PL3013855T3
PL3013855T3 PL14817835T PL14817835T PL3013855T3 PL 3013855 T3 PL3013855 T3 PL 3013855T3 PL 14817835 T PL14817835 T PL 14817835T PL 14817835 T PL14817835 T PL 14817835T PL 3013855 T3 PL3013855 T3 PL 3013855T3
Authority
PL
Poland
Prior art keywords
methods
factor viii
mutant factor
viii compositions
compositions
Prior art date
Application number
PL14817835T
Other languages
English (en)
Inventor
Wenjing Cao
Biao DONG
Original Assignee
Xiao, Weidong
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xiao, Weidong filed Critical Xiao, Weidong
Publication of PL3013855T3 publication Critical patent/PL3013855T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
PL14817835T 2013-06-24 2014-06-24 Zmutowany czynnik viii – kompozycje i sposoby wytwarzania PL3013855T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361838867P 2013-06-24 2013-06-24
EP14817835.3A EP3013855B1 (en) 2013-06-24 2014-06-24 Mutant factor viii compositions and methods
PCT/US2014/043777 WO2014209942A1 (en) 2013-06-24 2014-06-24 Mutant factor viii compositions and methods

Publications (1)

Publication Number Publication Date
PL3013855T3 true PL3013855T3 (pl) 2021-04-19

Family

ID=52142603

Family Applications (1)

Application Number Title Priority Date Filing Date
PL14817835T PL3013855T3 (pl) 2013-06-24 2014-06-24 Zmutowany czynnik viii – kompozycje i sposoby wytwarzania

Country Status (14)

Country Link
US (3) US20160102133A1 (pl)
EP (2) EP3904376B1 (pl)
CN (1) CN105431451B (pl)
CY (1) CY1124110T1 (pl)
DK (1) DK3013855T3 (pl)
ES (1) ES2837475T3 (pl)
HR (1) HRP20210031T1 (pl)
HU (1) HUE052074T2 (pl)
LT (1) LT3013855T (pl)
PL (1) PL3013855T3 (pl)
PT (1) PT3013855T (pl)
RS (1) RS61305B1 (pl)
SI (1) SI3013855T1 (pl)
WO (1) WO2014209942A1 (pl)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX388739B (es) * 2015-02-06 2025-03-20 Univ North Carolina Chapel Hill Casetes optimizados de expresión del gen humano del factor viii de coagulación y su uso.
EA202190827A1 (ru) * 2015-11-13 2021-11-30 Баксалта Инкорпорейтед Вирусные векторы, кодирующие рекомбинантные варианты fviii с повышенной экспрессией для генной терапии гемофилии a
US20210228742A1 (en) 2018-04-27 2021-07-29 Seattle Children's Hospital D/B/A Seattle Children's Research Institute In vivo gene therapy using intraosseous delivery of a lentiviralgene construct
US12091675B2 (en) 2018-07-16 2024-09-17 Takeda Pharmaceutical Company Limited Gene therapy of hemophilia a using viral vectors encoding recombinant FVIII variants with increased expression
US11795207B2 (en) 2021-03-30 2023-10-24 AAVnerGene Inc. Modified plasma clotting factor VIII and method of use thereof
WO2022211791A1 (en) * 2021-03-30 2022-10-06 AAVnerGene Inc. Modified plasma clotting factor viii and method of use thereof
EP4211153A4 (en) * 2021-11-25 2023-11-01 Sichuan Real&Best Biotech Co., Ltd. ENGINEERED HUMAN FVII1 WITH INCREASED SECRETION ABILITY AND COAGULATION ACTIVITY
WO2025180508A1 (en) * 2024-02-29 2025-09-04 Shanghai Vitalgen Biopharma Co., Ltd. Human factor viii variant expression cassettes and uses thereof for treating hemophilia a

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4501729A (en) 1982-12-13 1985-02-26 Research Corporation Aerosolized amiloride treatment of retained pulmonary secretions
US5364771A (en) 1992-04-07 1994-11-15 Emory University Hybrid human/porcine factor VIII
US6376463B1 (en) 1992-04-07 2002-04-23 Emory University Modified factor VIII
US5859204A (en) 1992-04-07 1999-01-12 Emory University Modified factor VIII
US5478745A (en) 1992-12-04 1995-12-26 University Of Pittsburgh Recombinant viral vector system
US20040092442A1 (en) 1996-04-24 2004-05-13 University Of Michigan Inactivation resistant factor VIII
US6759216B1 (en) 1998-11-06 2004-07-06 Emory University Glycosylated, low antigenicity low immunogenicity factor VIII
AU780231B2 (en) 1998-11-10 2005-03-10 University Of North Carolina At Chapel Hill, The Virus vectors and methods of making and administering the same
EP1038959A1 (en) 1999-03-17 2000-09-27 Aventis Behring Gesellschaft mit beschränkter Haftung Factor VIII without B-domain, comprising one or more insertions of a truncated intron I of factor IX
ATE318923T1 (de) 2000-06-01 2006-03-15 Univ North Carolina Doppelsträngige parvovirus-vektoren
PL206105B1 (pl) 2000-09-19 2010-07-30 Emory Universityemory University Zmodyfikowany ludzki czynnik VIII oraz sposób modyfikacji ludzkiego czynnika VIII ze zmniejszeniem reaktywności na przeciwciało hamujące i zachowaniem aktywności prokoagulacyjnej
EP1233064A1 (en) 2001-02-09 2002-08-21 Aventis Behring Gesellschaft mit beschränkter Haftung Modified factor VIII cDNA and its use for the production of factor VIII
ES2319745T3 (es) * 2001-10-05 2009-05-12 Expression Therapeutics, Llc Secuencias de acidos nucleicos y aminoacidos que codifican polipeptidos de factor viii de alto nivel de expresion, y metodos de uso.
EP1424344A1 (en) 2002-11-29 2004-06-02 Aventis Behring Gesellschaft mit beschränkter Haftung Modified cDNA factor VIII and its derivates
US7211559B2 (en) * 2003-10-31 2007-05-01 University Of Maryland, Baltimore Factor VIII compositions and methods
CA2547569C (en) * 2003-12-03 2013-04-16 University Of Rochester Recombinant factor viii having increased specific activity
EP2297330A4 (en) * 2008-06-04 2012-03-14 Bayer Healthcare Llc FVII MUTINES FOR THE TREATMENT OF MORBUS WILLEBRAND
JP2013532176A (ja) 2010-07-15 2013-08-15 ノヴォ ノルディスク アー／エス 安定化させた第ｖｉｉｉ因子バリアント
US8637448B2 (en) * 2010-09-14 2014-01-28 University Of Rochester Recombinant factor VIII having enhanced stability following mutation at the A1-C2 domain interface

Also Published As

Publication number Publication date
US20160102133A1 (en) 2016-04-14
PT3013855T (pt) 2021-01-13
EP3013855B1 (en) 2020-10-14
CN105431451B (zh) 2024-08-23
SI3013855T1 (sl) 2021-06-30
HUE052074T2 (hu) 2021-04-28
EP3904376A1 (en) 2021-11-03
CN105431451A (zh) 2016-03-23
LT3013855T (lt) 2021-01-25
EP3904376B1 (en) 2024-11-13
US20220144919A1 (en) 2022-05-12
US20190177399A1 (en) 2019-06-13
HRP20210031T1 (hr) 2021-05-14
CY1124110T1 (el) 2022-05-27
EP3013855A1 (en) 2016-05-04
ES2837475T3 (es) 2021-06-30
EP3013855A4 (en) 2017-12-13
RS61305B1 (sr) 2021-02-26
US11261234B2 (en) 2022-03-01
WO2014209942A1 (en) 2014-12-31
DK3013855T3 (da) 2021-01-11

Similar Documents

Publication Publication Date Title
IL273205A (en) Preparations and methods
IL289821A (en) Preparations and methods for immunotherapy
IL269461B (en) Cytidine-5-carboxamide modified nucleotide preparations and related methods
GB2521022B (en) Compositions and methods
IL286759A (en) Therapeutic methods and preparations
GB201308072D0 (en) Compositions and methods
SMT201900635T1 (it) Composizioni e metodi di attivazione della segnalazione dipendente dallo "stimolatore di geni interferone"
EP2951283A4 (en) Compositions and methods
IL245470B (en) Methods and preparations for delayed immunotherapy
IL243235A0 (en) Preparations and methods for immunotherapy
PT3013855T (pt) Composições de fator viii mutante e métodos
GB201305813D0 (en) Compositions and methods
GB201322456D0 (en) Radiotracer compositions and methods
EP2964610A4 (en) VINYL SULFON-BASED 18F LABELING COMPOSITIONS AND METHOD AND USES THEREOF
ZA201604587B (en) Testosterone gel compositions and related methods
GB201322617D0 (en) Methods and compositions
GB201312393D0 (en) Compositions and Methods
AU2013902874A0 (en) Compositions and methods
GB201319255D0 (en) Therapeutic compositions and methods
GB201308242D0 (en) Compositions and uses thereof